{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:07:39Z","timestamp":1768280859775,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T00:00:00Z","timestamp":1450051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T00:00:00Z","timestamp":1450051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The hepatitis B prevalence rate in adults is still at a high to intermediate level in China. Our purpose was to explore the incidence rate and protective immune barrier against hepatitis B in adults in China. A sample of 317961 participants was multi-screened for hepatitis B surface antigens (HBsAg) in a large-scale cohort of the National Hepatitis B Demonstration Project. A total of 5401 persons were newly-infected, representing an incidence rate of 0.81 (95%\u2009CI: 0.77\u20130.85) per 100 person-years after adjusted by gender and age. History of acquired immune deficiency syndrome, birth prior to 1992, coastal residence, family history of HBV and migrant worker status were significantly associated with higher incidence, while HBV vaccination and greater exercise with lower incidence. The hepatitis B surface antibody (HBsAb) positive rate was negatively correlated with the incidence rate of hepatitis B (r\u2009=\u2009\u22120.826). Linear fitting yielded an incidence rate of 1.23 plus 0.02 multiplied by HBsAb positive rate. The study firstly identified the HBsAg incidence rate, which was reduced to 0.1 per 100 person-years after vaccination coverage of about 64%. The protective immune barrier against hepatitis B needs to be established in individuals born prior to the advent of infant HBV vaccination.<\/jats:p>","DOI":"10.1038\/srep18334","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T10:35:46Z","timestamp":1450089346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Protective immune barrier against hepatitis B is needed in individuals born before infant HBV vaccination program in China"],"prefix":"10.1038","volume":"5","author":[{"given":"Shigui","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengbo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaijin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiansheng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chencheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanxia","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,14]]},"reference":[{"key":"BFsrep18334_CR1","doi-asserted-by":"crossref","unstructured":"EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57, 167-85 (2012).","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"BFsrep18334_CR2","doi-asserted-by":"crossref","unstructured":"Hepatitis B vaccines: WHO position paper\u2014recommendations. Vaccine 28, 589-90 (2010).","DOI":"10.1016\/j.vaccine.2009.10.110"},{"key":"BFsrep18334_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"YF Liaw","year":"2009","unstructured":"Liaw, Y. F. & Chu, C. M. Hepatitis B virus infection. Lancet 373, 582\u201392 (2009).","journal-title":"Lancet"},{"key":"BFsrep18334_CR4","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1111\/jgh.12684","volume":"29","author":"J Howell","year":"2014","unstructured":"Howell, J., Van Gemert, C., Lemoine, M., Thursz, M. & Hellard, M. An overview of hepatitis B prevalence, prevention and management in the Pacific Islands and Territories. J Gastroenterol Hepatol 29, 1854\u201366 (2014).","journal-title":"J Gastroenterol Hepatol"},{"key":"BFsrep18334_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/jama.2009.1024","volume":"302","author":"RP Beasley","year":"2009","unstructured":"Beasley, R. P. Development of hepatitis B vaccine. JAMA 302, 322\u20134 (2009).","journal-title":"JAMA"},{"key":"BFsrep18334_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2471\/BLT.08.059220","volume":"87","author":"M Rani","year":"2009","unstructured":"Rani, M., Yang, B. & Nesbit, R. Hepatitis B control by 2012 in the WHO Western Pacific Region: rationale and implications. Bull World Health Organ 87, 707\u201313 (2009).","journal-title":"Bull World Health Organ"},{"key":"BFsrep18334_CR7","unstructured":"Progress towards meeting the 2012 hepatitis B control milestone: WHO Western Pacific Region, 2011. Wkly Epidemiol Rec86, 180-8 (2011)."},{"key":"BFsrep18334_CR8","doi-asserted-by":"publisher","first-page":"J85","DOI":"10.1016\/j.vaccine.2012.10.082","volume":"31","author":"K Hennessey","year":"2013","unstructured":"Hennessey, K., Mendoza-Aldana, J., Bayutas, B., Lorenzo-Mariano, K. M. & Diorditsa, S. Hepatitis B control in the World Health Organization\u2019s Western Pacific Region: targets, strategies, status. Vaccine 31 Suppl 9, J85\u201392 (2013).","journal-title":"Vaccine"},{"key":"BFsrep18334_CR9","doi-asserted-by":"crossref","unstructured":"Haverkate, M. et al. Mandatory and recommended vaccination in the EU, Iceland and Norway: results of the VENICE 2010 survey on the ways of implementing national vaccination programmes. Euro Surveill 17 (2012).","DOI":"10.2807\/ese.17.22.20183-en"},{"key":"BFsrep18334_CR10","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott, J. J., Stevens, G. A., Groeger, J. & Wiersma, S. T. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212\u20139 (2012).","journal-title":"Vaccine"},{"key":"BFsrep18334_CR11","first-page":"5","volume":"1","author":"YS Chen","year":"2007","unstructured":"Chen, Y. S., Wang, X. X., Shang P. H. & Liang, X. F. The study of tendency of hepatitis B virus surface antigen in Chinese population. Chin J Exp Clin InfectDis (ElectronicVersion) 1, 5 (2007).","journal-title":"Chin J Exp Clin InfectDis (ElectronicVersion)"},{"key":"BFsrep18334_CR12","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","volume":"27","author":"X Liang","year":"2009","unstructured":"Liang, X. et al. Epidemiological serosurvey of hepatitis B in China\u2013declining HBV prevalence due to hepatitis B vaccination. Vaccine 27, 6550\u20137 (2009).","journal-title":"Vaccine"},{"key":"BFsrep18334_CR13","unstructured":"The basic situation of the population. (National Bureau of Statistics of China)."},{"key":"BFsrep18334_CR14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/hep.21612","volume":"45","author":"CM Chu","year":"2007","unstructured":"Chu, C. M. & Liaw, Y. F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 45, 1187\u201392 (2007).","journal-title":"Hepatology"},{"key":"BFsrep18334_CR15","unstructured":"Ministry of Science and Technology of the People\u2019s Republic of China, National medium and long-term science and technology development plan. (2006) Available at: http:\/\/www.most.gov.cn\/mostinfo\/xinxifenlei\/gjkjgh\/200811\/t20081129_65774.htm. (Accessed:11\/ 03\/ 2015)."},{"key":"BFsrep18334_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/1471-2458-12-272","volume":"12","author":"X Li","year":"2012","unstructured":"Li, X. et al. Hepatitis B virus infections and risk factors among the general population in Anhui Province, China: an epidemiological study. BMC Public Health 12, 272 (2012).","journal-title":"BMC Public Health"},{"key":"BFsrep18334_CR17","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0140-6736(07)60723-5","volume":"369","author":"J Liu","year":"2007","unstructured":"Liu, J. & Fan, D. Hepatitis B in China. Lancet 369, 1582\u20133 (2007).","journal-title":"Lancet"},{"key":"BFsrep18334_CR18","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1001\/jama.305.14.1500","volume":"305","author":"JM Torpy","year":"2011","unstructured":"Torpy, J. M., Burke, A. E. & Golub, R. M. JAMA patient page. Hepatitis B. JAMA 305, 1500 (2011).","journal-title":"JAMA"},{"key":"BFsrep18334_CR19","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","volume":"337","author":"WMHepatitis Lee","year":"1997","unstructured":"Lee, W.M. Hepatitis B virus infection. N Engl J Med 337, 1733\u201345 (1997).","journal-title":"N Engl J Med"},{"key":"BFsrep18334_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1017\/S0950268800001497","volume":"117","author":"WJ Edmunds","year":"1996","unstructured":"Edmunds, W. J. et al. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 117, 313\u201325 (1996).","journal-title":"Epidemiol Infect"},{"key":"BFsrep18334_CR21","doi-asserted-by":"crossref","unstructured":"Caley, M., Fowler, T., Greatrex, S. & Wood, A. Differences in hepatitis B infection rate between ethnic groups in antenatal women in Birmingham, United Kingdom, May 2004 to December 2008. Euro Surveill 17 (2012).","DOI":"10.2807\/ese.17.30.20228-en"},{"key":"BFsrep18334_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2807\/1560-7917.ES2015.20.13.21080","volume":"20","author":"EF Duffell","year":"2015","unstructured":"Duffell, E. F. & van de Laar, M. J. Survey of surveillance systems and select prevention activities for hepatitis B and C, European Union\/European Economic Area, 2009. Euro Surveill 20, 17\u201324 (2015).","journal-title":"Euro Surveill"},{"key":"BFsrep18334_CR23","first-page":"5","volume":"1","author":"YS Chen","year":"2007","unstructured":"Chen, Y. S., Wang, X. X. & Shang, P. H. The study of tendency of hepatitis B virus surface antigen in Chinese population. Chin J Exp Clin Infect Dis 1, 5 (2007).","journal-title":"Chin J Exp Clin Infect Dis"},{"key":"BFsrep18334_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0928-4346(96)82012-3","volume":"5","author":"GLL Xia","year":"1996","unstructured":"Xia, G. L. L., C.B. Cao, H. L. et al. Prevalence of hepatitis B and C virus infections in the conventional Chinese population: results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D and E virus infections in China, 1992. Int Hepatol Commun 5, 12 (1996).","journal-title":"Int Hepatol Commun"},{"key":"BFsrep18334_CR25","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMra0801644","volume":"359","author":"JL Dienstag","year":"2008","unstructured":"Dienstag, J. L. Hepatitis B virus infection. N Engl J Med 359, 1486\u2013500 (2008).","journal-title":"N Engl J Med"},{"key":"BFsrep18334_CR26","unstructured":"Application guide for science and technology project of a major infectious disease prevention and control (The Ministry of Health of China, 2008)."},{"key":"BFsrep18334_CR27","doi-asserted-by":"publisher","first-page":"e47808","DOI":"10.1371\/journal.pone.0047808","volume":"7","author":"SG Yang","year":"2012","unstructured":"Yang, S. G. et al. Effectiveness of HBV vaccination in infants and prediction of HBV prevalence trend under new vaccination plan: findings of a large-scale investigation. PLoS One 7, e47808 (2012).","journal-title":"PLoS One"},{"key":"BFsrep18334_CR28","unstructured":"Li, L. (ed.) Standard operation procedure for major projects of national science and technology of infectious disease: the community comprehensive prevention and control of major infectious diseases, 89 (Science Press, Beijing, 2012)."},{"key":"BFsrep18334_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0168-8278(02)00382-3","volume":"38","author":"R Aggarwal","year":"2003","unstructured":"Aggarwal, R., Ghoshal, U. C. & Naik, S. R. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol 38, 215\u201322 (2003).","journal-title":"J Hepatol"},{"key":"BFsrep18334_CR30","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jhep.2012.05.021","volume":"57","author":"YH Ni","year":"2012","unstructured":"Ni, Y. H. et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 57, 730\u20135 (2012).","journal-title":"J Hepatol"},{"key":"BFsrep18334_CR31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/oxfordjournals.aje.a117321","volume":"140","author":"SA Marion","year":"1994","unstructured":"Marion, S. A., Tomm Pastore, M., Pi, D. W. & Mathias, R. G. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 140, 734\u201346 (1994).","journal-title":"Am J Epidemiol"},{"key":"BFsrep18334_CR32","first-page":"1","volume":"54","author":"EE Mast","year":"2005","unstructured":"Mast, E. E. et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children and adolescents. MMWR Recomm Rep 54, 1\u201331 (2005).","journal-title":"MMWR Recomm Rep"},{"key":"BFsrep18334_CR33","first-page":"1199","volume":"32","author":"FQ Cui","year":"2011","unstructured":"Cui, F. Q. [Technical guide for adult hepatitis B immunization in China]. Zhonghua Liu Xing Bing Xue Za Zhi 32, 1199\u2013203 (2011).","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"BFsrep18334_CR34","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1016\/j.vaccine.2014.02.093","volume":"32","author":"K Hennessey","year":"2014","unstructured":"Hennessey, K. et al. Are we there yet? Assessing achievement of vaccine-preventable disease goals in WHO\u2019s Western Pacific Region. Vaccine 32, 4259\u201366 (2014).","journal-title":"Vaccine"},{"key":"BFsrep18334_CR35","doi-asserted-by":"crossref","unstructured":"Yao, J. et al. The response of hepatitis B vaccination on seronegative adults with different vaccination schedules. Hum Vaccin Immunother 0 (2015).","DOI":"10.4161\/21645515.2014.985500"},{"key":"BFsrep18334_CR36","first-page":"193","volume":"24","author":"M Chandra","year":"2003","unstructured":"Chandra, M. et al. Prevalence, risk factors and genotype distribution of HCV and HBV infection in the tribal population: a community based study in south India. Trop Gastroenterol 24, 193\u20135 (2003).","journal-title":"Trop Gastroenterol"},{"key":"BFsrep18334_CR37","doi-asserted-by":"crossref","unstructured":"Hansen, N. et al. Hepatitis B prevalence in Denmark - an estimate based on nationwide registers and a national screening programme, as on 31 December 2007. Euro Surveill 18 (2013).","DOI":"10.2807\/1560-7917.ES2013.18.47.20637"},{"key":"BFsrep18334_CR38","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1473-3099(14)70946-6","volume":"14","author":"F Zhang","year":"2014","unstructured":"Zhang, F. et al. HIV, hepatitis B virus and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010-12: a retrospective observational cohort study. Lancet Infect Dis 14, 1065\u201372 (2014).","journal-title":"Lancet Infect Dis"},{"key":"BFsrep18334_CR39","unstructured":"Application guide for science and technology project of a major infectious disease prevention and control (The Ministry of Health of China, 2013)."},{"key":"BFsrep18334_CR40","unstructured":"the Zhejiang province population sampling survey data the main bulletin in 2012 (Zhejiang Provincial Bureau of Statistics, Hangzhou, 2012)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep18334","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep18334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:54:28Z","timestamp":1672966468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep18334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,14]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,11,22]]}},"alternative-id":["BFsrep18334"],"URL":"https:\/\/doi.org\/10.1038\/srep18334","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,14]]},"assertion":[{"value":"6 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18334"}}